CON: Is liver organ allocation with MMaT-3 appropriate prioritization for patients with liver cancer?
- 1 March 2023
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 21 (3) , 73-75
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- The Impact of Median Model for End‐Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular CarcinomaLiver Transplantation, 2021
- Patterns and Predictors of Mortality After Waitlist Dropout of Patients With Hepatocellular Carcinoma Awaiting Liver TransplantationTransplantation, 2019
- Hepatocellular CarcinomaNew England Journal of Medicine, 2019
- Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy changeAmerican Journal of Transplantation, 2018
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver DiseasesHepatology, 2018
- Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver TransplantationAnnals of Surgery, 2017
- Neoadjuvant Locoregional Therapy and Recurrent Hepatocellular Carcinoma after Liver TransplantationJournal of the American College of Surgeons, 2017
- Removing patients from the liver transplant wait list: A survey of US liver transplant programsLiver Transplantation, 2008
- Partial Necrosis on Hepatocellular Carcinoma Nodules Facilitates Tumor Recurrence after Liver TransplantationTransplantation, 2004